Skip to main content
SOLTF
OTC Life Sciences

AbbVie Pays $100M Upfront in $1.5B Bowel Disease Licensing Deal

Tom Rudovsky · Reported by Seeking Alpha
More coverage: Healthcare
Sentiment info
Positive
Importance info
7
Price
$8.5
Mkt Cap
$787.229M
52W Low
$4.9
52W High
$22.782
52W Position info
73% above low
Off High info
63% below high
Rel. Volume
Market data snapshot near publication time

SOLTF sits 73% above its 52-week low of $4.9.

Summary

Nxera Pharma licensed global rights to its EP4 agonist NXE0033744 for inflammatory bowel disease to AbbVie in a deal worth up to $1.5B. Nxera gets $100M upfront plus up to $1.37B in development and commercial milestones and tiered royalties on net sales. The upfront alone is transformative for a company of Nxera's size and is expected to boost Q4 2026 results. Nxera had discontinued NXE0033744 studies in IBD last year as part of a restructuring, so this revives the program with a large partner. For AbbVie, the deal is a modest bolt-on that adds an early-stage immunology asset to its pipeline and builds on an existing neuroscience discovery collaboration between the two firms.

At the time of this announcement, SOLTF was trading at $8.50 on OTC in the Life Sciences sector, with a market capitalization of approximately $787.2M. The 52-week trading range was $4.90 to $22.78. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Seeking Alpha.


Price Chart

Share this article

Copied!

SOLTF - Latest Insights